Let there be oxygen and T cells
The stroma of solid tumors can exclude or limit immune infiltration, or lead to the recruitment of tumor-promoting rather than tumor-attacking immune cells. This finding was reported by Jayaprakash et al. in this issue of the JCI, and it was particularly prominent in the hypoxic zones of tumors in t...
Gespeichert in:
| Veröffentlicht in: | The Journal of clinical investigation 2018-11, Vol.128 (11), p.4761-4763 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4763 |
|---|---|
| container_issue | 11 |
| container_start_page | 4761 |
| container_title | The Journal of clinical investigation |
| container_volume | 128 |
| creator | Walker, Paul R |
| description | The stroma of solid tumors can exclude or limit immune infiltration, or lead to the recruitment of tumor-promoting rather than tumor-attacking immune cells. This finding was reported by Jayaprakash et al. in this issue of the JCI, and it was particularly prominent in the hypoxic zones of tumors in the transgenic adenocarcinoma of the mouse prostate (TRAMP) cancer models. A current clinical goal of immune checkpoint blockade (ICB) is to extend its utility to more patients by converting immunologically "cold" tumors that do not provoke a strong immunological response to "hot" tumors that are invaded by swarms of T cells. When the underlying cause is hypoxia linked, the therapeutic combination of simultaneous targeting of hypoxia and immune checkpoints merits exploration in future clinical trials. |
| doi_str_mv | 10.1172/JCI124305 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6205379</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2120189540</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-b096b8c23931aad785a934053c757cfc374bca1e53ae9ec44da96b4d3a1f51de3</originalsourceid><addsrcrecordid>eNpdkM1OwzAQhC0EoqVw4AUgEhc4BGyv3cQXJFTxU1SJSzlbjrNpU6VxsRNE355ULRVw2sN-OzszhJwzestYwu9eR2PGBVB5QPpMyjROOaSHpE8pZ7FKIO2RkxAWlDIhpDgmPaDA6ZDyPrmcYBM1c_QYZRi5r_UM68jUeTSNLFZVOCVHhakCnu3mgLw_PU5HL_Hk7Xk8epjEVlBo4oyqYZZaDgqYMXmSSqNAUAk2kYktLCQis4ahBIMKrRC56Q5EDoYVkuUIA3K_1V212RJzi3XjTaVXvlwav9bOlPrvpi7neuY-9ZB3XxLVCVzvBLz7aDE0elmGTQRTo2uD5oxTlirZ2R2Qq3_owrW-7uJ1FAAoDmIjeLOlrHcheCz2ZhjVm9r1vvaOvfjtfk_-9AzfzeR6mA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2133392349</pqid></control><display><type>article</type><title>Let there be oxygen and T cells</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Ovid Autoload</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Walker, Paul R</creator><creatorcontrib>Walker, Paul R</creatorcontrib><description>The stroma of solid tumors can exclude or limit immune infiltration, or lead to the recruitment of tumor-promoting rather than tumor-attacking immune cells. This finding was reported by Jayaprakash et al. in this issue of the JCI, and it was particularly prominent in the hypoxic zones of tumors in the transgenic adenocarcinoma of the mouse prostate (TRAMP) cancer models. A current clinical goal of immune checkpoint blockade (ICB) is to extend its utility to more patients by converting immunologically "cold" tumors that do not provoke a strong immunological response to "hot" tumors that are invaded by swarms of T cells. When the underlying cause is hypoxia linked, the therapeutic combination of simultaneous targeting of hypoxia and immune checkpoints merits exploration in future clinical trials.</description><identifier>ISSN: 0021-9738</identifier><identifier>EISSN: 1558-8238</identifier><identifier>DOI: 10.1172/JCI124305</identifier><identifier>PMID: 30320602</identifier><language>eng</language><publisher>United States: American Society for Clinical Investigation</publisher><subject>Adenocarcinoma ; Animal models ; Biomarkers ; Biomedical research ; Cancer therapies ; Chemotherapy ; Clinical trials ; Cytotoxicity ; Hypoxia ; Immune checkpoint ; Immunology ; Immunotherapy ; Lymphocytes ; Lymphocytes T ; Metastases ; Prostate cancer ; Solid tumors ; Stroma ; Tumors</subject><ispartof>The Journal of clinical investigation, 2018-11, Vol.128 (11), p.4761-4763</ispartof><rights>Copyright American Society for Clinical Investigation Nov 2018</rights><rights>Copyright © 2018, American Society for Clinical Investigation 2018 American Society for Clinical Investigation</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-b096b8c23931aad785a934053c757cfc374bca1e53ae9ec44da96b4d3a1f51de3</citedby><cites>FETCH-LOGICAL-c403t-b096b8c23931aad785a934053c757cfc374bca1e53ae9ec44da96b4d3a1f51de3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205379/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205379/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30320602$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Walker, Paul R</creatorcontrib><title>Let there be oxygen and T cells</title><title>The Journal of clinical investigation</title><addtitle>J Clin Invest</addtitle><description>The stroma of solid tumors can exclude or limit immune infiltration, or lead to the recruitment of tumor-promoting rather than tumor-attacking immune cells. This finding was reported by Jayaprakash et al. in this issue of the JCI, and it was particularly prominent in the hypoxic zones of tumors in the transgenic adenocarcinoma of the mouse prostate (TRAMP) cancer models. A current clinical goal of immune checkpoint blockade (ICB) is to extend its utility to more patients by converting immunologically "cold" tumors that do not provoke a strong immunological response to "hot" tumors that are invaded by swarms of T cells. When the underlying cause is hypoxia linked, the therapeutic combination of simultaneous targeting of hypoxia and immune checkpoints merits exploration in future clinical trials.</description><subject>Adenocarcinoma</subject><subject>Animal models</subject><subject>Biomarkers</subject><subject>Biomedical research</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Cytotoxicity</subject><subject>Hypoxia</subject><subject>Immune checkpoint</subject><subject>Immunology</subject><subject>Immunotherapy</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Metastases</subject><subject>Prostate cancer</subject><subject>Solid tumors</subject><subject>Stroma</subject><subject>Tumors</subject><issn>0021-9738</issn><issn>1558-8238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkM1OwzAQhC0EoqVw4AUgEhc4BGyv3cQXJFTxU1SJSzlbjrNpU6VxsRNE355ULRVw2sN-OzszhJwzestYwu9eR2PGBVB5QPpMyjROOaSHpE8pZ7FKIO2RkxAWlDIhpDgmPaDA6ZDyPrmcYBM1c_QYZRi5r_UM68jUeTSNLFZVOCVHhakCnu3mgLw_PU5HL_Hk7Xk8epjEVlBo4oyqYZZaDgqYMXmSSqNAUAk2kYktLCQis4ahBIMKrRC56Q5EDoYVkuUIA3K_1V212RJzi3XjTaVXvlwav9bOlPrvpi7neuY-9ZB3XxLVCVzvBLz7aDE0elmGTQRTo2uD5oxTlirZ2R2Qq3_owrW-7uJ1FAAoDmIjeLOlrHcheCz2ZhjVm9r1vvaOvfjtfk_-9AzfzeR6mA</recordid><startdate>20181101</startdate><enddate>20181101</enddate><creator>Walker, Paul R</creator><general>American Society for Clinical Investigation</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>S0X</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20181101</creationdate><title>Let there be oxygen and T cells</title><author>Walker, Paul R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-b096b8c23931aad785a934053c757cfc374bca1e53ae9ec44da96b4d3a1f51de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adenocarcinoma</topic><topic>Animal models</topic><topic>Biomarkers</topic><topic>Biomedical research</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Cytotoxicity</topic><topic>Hypoxia</topic><topic>Immune checkpoint</topic><topic>Immunology</topic><topic>Immunotherapy</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Metastases</topic><topic>Prostate cancer</topic><topic>Solid tumors</topic><topic>Stroma</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Walker, Paul R</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Walker, Paul R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Let there be oxygen and T cells</atitle><jtitle>The Journal of clinical investigation</jtitle><addtitle>J Clin Invest</addtitle><date>2018-11-01</date><risdate>2018</risdate><volume>128</volume><issue>11</issue><spage>4761</spage><epage>4763</epage><pages>4761-4763</pages><issn>0021-9738</issn><eissn>1558-8238</eissn><abstract>The stroma of solid tumors can exclude or limit immune infiltration, or lead to the recruitment of tumor-promoting rather than tumor-attacking immune cells. This finding was reported by Jayaprakash et al. in this issue of the JCI, and it was particularly prominent in the hypoxic zones of tumors in the transgenic adenocarcinoma of the mouse prostate (TRAMP) cancer models. A current clinical goal of immune checkpoint blockade (ICB) is to extend its utility to more patients by converting immunologically "cold" tumors that do not provoke a strong immunological response to "hot" tumors that are invaded by swarms of T cells. When the underlying cause is hypoxia linked, the therapeutic combination of simultaneous targeting of hypoxia and immune checkpoints merits exploration in future clinical trials.</abstract><cop>United States</cop><pub>American Society for Clinical Investigation</pub><pmid>30320602</pmid><doi>10.1172/JCI124305</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-9738 |
| ispartof | The Journal of clinical investigation, 2018-11, Vol.128 (11), p.4761-4763 |
| issn | 0021-9738 1558-8238 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6205379 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Ovid Autoload; PubMed Central; Alma/SFX Local Collection |
| subjects | Adenocarcinoma Animal models Biomarkers Biomedical research Cancer therapies Chemotherapy Clinical trials Cytotoxicity Hypoxia Immune checkpoint Immunology Immunotherapy Lymphocytes Lymphocytes T Metastases Prostate cancer Solid tumors Stroma Tumors |
| title | Let there be oxygen and T cells |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T17%3A37%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Let%20there%20be%20oxygen%20and%20T%20cells&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=Walker,%20Paul%20R&rft.date=2018-11-01&rft.volume=128&rft.issue=11&rft.spage=4761&rft.epage=4763&rft.pages=4761-4763&rft.issn=0021-9738&rft.eissn=1558-8238&rft_id=info:doi/10.1172/JCI124305&rft_dat=%3Cproquest_pubme%3E2120189540%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2133392349&rft_id=info:pmid/30320602&rfr_iscdi=true |